Zileuton and Exhaled Nitric Oxide in Asthmatics

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gelb, Arthur F., M.D.
• Treatments: Hydroxyurea; Nitric Oxide; Zileuton

Criteria

Inclusion Criteria:

• Non-smoking

• Moderate to severe persistent asthmatics

• Clinically stable X 6 weeks on Advair 250/50 bid for at least 12 months

Exclusion Criteria:

• No leukotriene synthesis inhibitors or receptor antagonists for 6 weeks